Stay updated on Nivolumab+SAbR in Metastatic Clear Cell Renal Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab+SAbR in Metastatic Clear Cell Renal Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab+SAbR in Metastatic Clear Cell Renal Cell Carcinoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page now displays the record for the nivolumab and SAbR study for metastatic clear cell renal cell carcinoma, including its terminated status, results, eligibility criteria, outcomes, and study documents, instead of a 403 error.
    Difference
    52%
    Check dated 2026-11-07T16:14:43.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.2 to v3.8.0, while the requested study record still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T16:34:57.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A sitewide banner announces NIH website updates and says that some NIH content may use “Super Intelligence” instead of “Artificial Intelligence” during the transition.
    Difference
    1%
    Check dated 2026-10-24T22:23:14.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The page now displays the ClinicalTrials.gov site frame instead of the 403 error, with the revision label updated to v3.7.2; the study content area appears blank.
    Difference
    0.6%
    Check dated 2026-10-17T22:24:29.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision label changes from v3.7.0 to v3.7.1; the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T22:16:15.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    There are no additions or deletions in the provided changes. The page context shows a 403 Forbidden error, indicating restricted access.
    Difference
    0.2%
    Check dated 2026-09-26T22:01:42.000Z thumbnail image

Stay in the know with updates to Nivolumab+SAbR in Metastatic Clear Cell Renal Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab+SAbR in Metastatic Clear Cell Renal Cell Carcinoma Clinical Trial page.